Transderm-nitro

   
Google
 
Web NewDrugInformation.com

Transderm-nitro


Drug - Transderm-nitro
The trade name of the product as shown on the labeling.

Dosage - FILM, EXTENDED RELEASE; TRANSDERMAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Nitroglycerin
Multiple ingredients are in alphabetical order.

Strength - 0.1MG/HR
The potency of the active ingredient(s), Nitroglycerin. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Transderm-nitro. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020144
The FDA assigned number to Transderm-nitro. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Transderm-nitro. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Feb 27, 1996
The date Transderm-nitro was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Transderm-nitro. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Transderm-nitro is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Pharmaceuticals Corp
The full name of the firm holding legal responsibility for the new application of Transderm-nitro.

Transderm-nitro